News & Views
News,
Telix today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET agent, Zircaix® (TLX250-CDx)…
Read more
Prostate Cancer Awareness Month,
During Prostate Cancer Awareness, Telix is speaking with the physicians, advocates and patients on the frontlines of fighting prostate…
Read more
Telix today announces that primary results from its Phase III ZIRCON trial have been published in The Lancet Oncology, reporting that Telix’s first-in-class investigational PET agent, TLX250-CDx (Zircaix®, 89Zr-girentuximab), is…
Read more
During Prostate Cancer Awareness, Telix is speaking with the physicians, advocates and patients on the frontlines of fighting prostate…
Read more
Telix today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination…
Read more
Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2]…
Read more
Telix today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to…
Read more
Telix today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise…
Read more
Telix today advises that it will release its financial results for the half-year ended 30 June 2024 on Thursday 22 August…
Read more
News,
Telix today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara®1, 18F-floretyrosine or 18F-FET) an investigational positron emission tomography (PET) agent for…
Read more